



Erratum

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035

<https://doi.org/10.2337/dc17-er06c>

Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, and Melanie Davies, on behalf of the LixiLan-O Trial Investigators

In the Research Design and Methods section of the abstract of the above-mentioned article, the value of “<5.6 mmol/mol” should read “<5.6 mmol/L.”

The online issue has been corrected to reflect this change.